Press Release

Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development

Paris (France), 20th April 2017 – Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enable...

Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development

Paris (France), 11th April 2017 – Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that e...

Eyevensys reçoit l’autorisation de l’ANSM pour lancer la première étude clinique utilisant sa plateforme EyeCET

Paris (France), 11 Avril 2017 - Eyevensys, société de biotechnologie spécialisée dans le développement d’ EyeCET, première plateforme de thérapie génique non virale oculair...

Eyevensys Appoints Leading Life Sciences Executive and Ophthalmology Expert Dr. Garth Cumberlidge as Chairman

Paris (France), 21th March 2017 – Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technol...

Eyevensys Announces Series A Extension Bringing Total Capital Raised to €9 Million

Paris (France), 15th September 2016 – Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral technology that allows a ...

Go to the document